Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02953379

Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis

Phase III, National, Multicenter, Randomized, Single-blind, Non-inferiority to Compare the Efficacy of Mometasone Nasal Gel Compared to Mometasone Nasal Spray in the Treatment of Persistent or Intermittent Allergic Rhinitis in Adults

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
EMS · Industry
Sex
All
Age
12 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the non-inferiority of the clinical efficacy of the mometasone nasal gel in the treatment of allergic rhinitis.

Conditions

Interventions

TypeNameDescription
DRUGEMS Mometasone gelThe patient should administer 2 spray in each nostril, once daily.
DRUGMometasone spray nasalThe patient should administer 2 spray in each nostril, once daily.

Timeline

Start date
2019-05-01
Primary completion
2019-12-01
Completion
2020-03-01
First posted
2016-11-02
Last updated
2020-11-04

Source: ClinicalTrials.gov record NCT02953379. Inclusion in this directory is not an endorsement.

Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis (NCT02953379) · Clinical Trials Directory